Erica Witek
Physician Assistant · Mountain View
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
On the public record
- 1 Medical Board action on record
Offices
4 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Erica Witek’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A62314 · Current
Licensed to practise in California · since 1997 · expires 2027-04-30 · St. George'S University School of Medicine. Board flags: Public Reprimand.
Matched on the licence number without its letter prefix; check the name before relying on it.
Public record actions
| 2019-08-21 | Board disciplineDiscipline | Public reprimand. · 8002015014249 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$75,166
Medicare paid this office $75,166 for 411 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 161 | $23,242 | $105 |
| Short return visit (20+ min) | 159 | $15,242 | $75 |
| Long return visit (40+ min) | 77 | $12,998 | $151 |
| New patient visit (30+ min) | 41 | $3,440 | $84 |
| Surgical repair of vaginal defect using an endoscope | 25 | $3,078 | $123 |
See all 12 services
| Return visit (30+ min) | 161 | $23,242 | $105 |
| Short return visit (20+ min) | 159 | $15,242 | $75 |
| Long return visit (40+ min) | 77 | $12,998 | $151 |
| New patient visit (30+ min) | 41 | $3,440 | $84 |
| Surgical repair of vaginal defect using an endoscope | 25 | $3,078 | $123 |
| Fitting and insertion of vaginal support device | 33 | $2,457 | $65 |
| Pessary, reusable, non rubber, any type | 39 | $2,285 | $52 |
| Short return visit | 41 | $2,239 | $50 |
| Creation of sling around urethra in female to control leakage | 32 | $1,806 | $56 |
| New patient visit (45+ min) | 13 | $1,651 | $127 |
| Repair of herniated rectum into vaginal wall | 20 | $830 | $41 |
| New patient visit (15+ min) | 12 | $653 | $54 |
Procedures Medicare counted
| Removal of the uterus | 21 | More than 93% of doctors who do this |
Who their Medicare patients are
411 Original Medicare patients in 2024. Average age 78 · Women 100% · Also on Medicaid 9% · Health risk score 0.91. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 62% · Depression 20% · Diabetes 19% · Coronary heart disease 15% · Chronic kidney disease 15% · Cancer 15% · Atrial fibrillation 11% · Heart failure 9% · COPD 7% · Dementia 6% · Stroke 5%.
The office billed $300,963, Medicare allowed $98,394 and paid $75,166; for 931 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 411 | 931 | 78 | 0.91 | $300,963 | $75,166 |
| 2023 | 207 | 1,291 | 77 | 1.03 | $169,199 | $38,853 |
| 2022 | 157 | 11,548 | 75 | 1.83 | $618,103 | $204,709 |
| 2021 | 16 | 45 | 67 | 1.93 | $5,020 | $2,079 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Long return visit (40+ min) | 55 | $8,978 | $143 |
| Return visit (30+ min) | 57 | $6,541 | $101 |
| Insertion of lower leg neurostimulator electrode | 24 | $4,544 | $106 |
| Short return visit (20+ min) | 44 | $3,696 | $74 |
| Surgical repair of vaginal defect using an endoscope | 18 | $2,034 | $113 |
| Creation of sling around urethra in female to control leakage | 22 | $1,259 | $57 |
| Repair of herniated rectum into vaginal wall | 16 | $617 | $39 |
| Blood test, comprehensive group of blood chemicals | 12 | $124 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 13 | $99 | $8 |
2022: 23 services
| Return visit (30+ min) | 42 | $4,330 | $83 |
| Long return visit (40+ min) | 25 | $3,639 | $117 |
| Administration of chemotherapy into vein, 1 hour or less | 19 | $1,912 | $87 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 33 | $1,854 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 31 | $1,765 | $43 |
| Blood test, comprehensive group of blood chemicals | 88 | $1,284 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 91 | $967 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 16 | $880 | $14 |
| Ferritin (blood protein) level | 48 | $828 | $13 |
| Gammaglobulin (immune system protein) measurement | 22 | $738 | $9 |
| Short return visit (20+ min) | 11 | $706 | $54 |
| Injection of drug or substance under skin or into muscle | 47 | $608 | $9 |
| Iron binding capacity | 42 | $463 | $9 |
| Lactate dehydrogenase (enzyme) level | 54 | $426 | $6 |
| Iron level | 42 | $342 | $6 |
| Cyanocobalamin (vitamin b-12) level | 22 | $340 | $15 |
| Carcinoembryonic antigen (cea) protein level | 12 | $297 | $19 |
| Insertion of needle into vein for collection of blood sample | 68 | $253 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 32 | $55 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 28 | $35 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 26 | $33 | None |
| Unclassified drugs | 17 | $13 | None |
| Infusion, normal saline solution, 250 cc | 12 | $8 | None |
Medicaid work
$12,712 in 2022
Medicaid paid $12,712 for 467 billed services this clinician did in 2022, up to 47 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 159 | $8,929 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 22 | $1,709 |
| Pure tone audiometry (threshold); air only | 66 | $858 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 75 | $827 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 64 | $252 |
| Bilateral quantitative screening test of visual acuity | 63 | $74 |
| Administration of patient-focused health risk assessment instrument (eg, health hazard appraisal) with scoring and documentation, per standardized instrument | 18 | $64 |
| 2022 | 467 | 7 | 47 | $12,712 |
| 2021 | 1,908 | 15 | 68 | $54,840 |
See the largest Medicaid services in earlier years
2021
| Short return visit (20+ min) | 537 | $29,893 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 73 | $6,584 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 58 | $5,978 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 129 | $2,640 |
| Pure tone audiometry (threshold); air only | 243 | $2,446 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | 59 | $2,190 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 138 | $1,885 |
| New patient visit (30+ min) | 14 | $1,294 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 234 | $977 |
| Administration of patient-focused health risk assessment instrument (eg, health hazard appraisal) with scoring and documentation, per standardized instrument | 93 | $326 |
| Blood test, lipids (cholesterol and triglycerides) | 19 | $243 |
| Hemoglobin A1C level | 17 | $151 |
Drugs they prescribed that Part D paid
$329,801
Pharmacies billed $329,801 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (14 of 790) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
444 generic and fewer than 11 brand-name prescriptions · $329,801 in drug cost · 174 antibiotic prescriptions to 125 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gemtesa | 179 | $193,674 | $1,082 |
| Myrbetriq | 82 | $80,477 | $981 |
| Premarin | 46 | $19,711 | $428 |
| Estring | 27 | $14,124 | $523 |
| Estradiol | 115 | $8,438 | $73 |
See all 10 drugs
| Gemtesa | 179 | $193,674 | $1,082 |
| Myrbetriq | 82 | $80,477 | $981 |
| Premarin | 46 | $19,711 | $428 |
| Estring | 27 | $14,124 | $523 |
| Estradiol | 115 | $8,438 | $73 |
| Methenamine Hippurate | 22 | $1,602 | $73 |
| Nitrofurantoin Mono-Macro | 40 | $407 | $10 |
| Cephalexin | 53 | $316 | $6 |
| Gabapentin | 33 | $288 | $9 |
| Sulfamethoxazole-Trimethoprim | 61 | $127 | $2 |
Year by year
| 2024 | 790 | 341 | 2% (14) | None | $329,801 |
| 2023 | 261 | 174 | None | 43% | $74,967 |
| 2022 | 142 | 61 | 13% (18) | None | $11,410 |
| 2021 | 111 | 17 | 0% (0) | None | $11,376 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Gemtesa | 43 | $38,545 | $896 |
| Myrbetriq | 21 | $20,471 | $975 |
| Premarin | 12 | $5,513 | $459 |
| Estradiol | 24 | $3,756 | $157 |
| Nitrofurantoin Mono-Macro | 61 | $763 | $13 |
| Cephalexin | 18 | $197 | $11 |
| Sulfamethoxazole-Trimethoprim | 11 | $30 | $3 |
2021: 1 drug
| Losartan | 12 | $113 | $9 |
Money from drug and device companies
$63 in 2025
| 2025 | 1 | 2 | None | $63 |
| 2024 | 3 | 6 | None | $452 |
| 2023 | 6 | 9 | None | $547 |
| 2022 | 31 | 84 | None | $2,056 |
| 2021 | 12 | 46 | None | $904 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Gemtesa | $63 | 2 payments
|
See all 2 published payments
| Sumitomo Pharma America | Meals · 2025-12-08 | Gemtesa | $31 |
| Sumitomo Pharma America | Meals · 2025-08-27 | Gemtesa | $32 |
See earlier years (2024, 2023, 2022, 2021)
2024: $452
| Axonics | Axonics | $327 | 4 payments
|
| Abbvie | Botox | $107 | 1 payment
|
| Valencia Technologies | Ecoin Device Kit | $18 | 1 payment
|
2023: $547
| Novartis Pharmaceuticals | Tabrecta | $323 | 4 payments
|
| Medtronic | Interstim | $134 | 1 payment
|
| Incyte | Jakafi | $28 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $24 | 1 payment
|
| Amgen | Kyprolis | $22 | 1 payment
|
| Janssen Biotech | None | $15 | 1 payment
|
2022: $2,056
| Novartis Pharmaceuticals | Kisqali | $238 | 7 payments
|
| Seagen | Tukysa | $220 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $137 | 5 payments
|
| Novo Nordisk | Rybelsus | $112 | 1 payment
|
| Foundation Medicine | Foundationone | $108 | 4 payments
|
| Exelixis | Cabometyx | $105 | 4 payments
|
| G1 Therapeutics | Cosela | $100 | 1 payment
|
| Amgen | Kyprolis | $97 | 5 payments
|
| Pfizer | Bosulif | $97 | 5 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $82 | 5 payments
|
| Eisai | Lenvima | $77 | 4 payments
|
| Servier Pharmaceuticals | Tibsovo | $68 | 3 payments
|
| Regeneron Healthcare Solutions | Libtayo | $62 | 2 payments
|
| TerSera Therapeutics | Xermelo | $56 | 3 payments
|
| GlaxoSmithKline | Blenrep | $52 | 3 payments
|
| Incyte | Jakafi | $43 | 2 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $42 | 3 payments
|
| Lilly USA | Trulicity | $41 | 3 payments
|
| RedHill Biopharma | Talicia | $38 | 2 payments
|
| Gilead Sciences | Trodelvy | $38 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $37 | 2 payments
|
| Abbvie | Venclexta | $29 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $29 | 2 payments
|
| Acrotech Biopharma | Beleodaq | $24 | 1 payment
|
| ADC Therapeutics America | None | $22 | 1 payment
|
| Genentech USA | Tecentriq | $20 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $20 | 1 payment
|
| Taiho Oncology | Lonsurf | $17 | 1 payment
|
| Kite Pharma | None | $16 | 1 payment
|
| Helsinn Therapeutics (U.S.) | Truseltiq | $15 | 1 payment
|
| Pharmacosmos Therapeutics | Monoferric | $15 | 1 payment
|
2021: $904
| AstraZeneca Pharmaceuticals LP | Farxiga | $198 | 6 payments
|
| RedHill Biopharma | Talicia | $169 | 10 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $107 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $84 | 5 payments
|
| Lilly USA | Trulicity | $81 | 5 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $75 | 4 payments
|
| Merck Sharp & Dohme | Januvia | $72 | 5 payments
|
| Amarin Pharma | Vascepa | $47 | 3 payments
|
| Novo Nordisk | None | $29 | 2 payments
|
| Phadia US | Immunocap | $18 | 1 payment
|
| Sanofi Pasteur | Vaxelis | $13 | 1 payment
|
| Eisai | Dayvigo | $12 | 1 payment
|
Professional record
- NPI
- 1801487095
- Licence
- CA 62314, NC 001010348California A62314: Current · expires 2027-04-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant, surgical (363AS0400X); Physician assistant (363A00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2021-01-29
- NPI last updated
- 2023-05-01
- NPI record certified
- 2023-05-01
This is when the NPI record was last certified, not a medical board exam.